Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Immune Dysregulatory Disorders by Shahrzad, Bakhtiar et al.
REVIEW
published: 13 November 2019
doi: 10.3389/fped.2019.00461















This article was submitted to
Pediatric Immunology,
a section of the journal
Frontiers in Pediatrics
Received: 16 July 2019
Accepted: 23 October 2019
Published: 13 November 2019
Citation:
Bakhtiar S, Fekadu J, Seidel MG and






Allogeneic Hematopoietic Stem Cell
Transplantation for Congenital
Immune Dysregulatory Disorders
Shahrzad Bakhtiar 1*, Julia Fekadu 1, Markus G. Seidel 2 and Eleonora Gambineri 3,4
on behalf of Inborn Errors Working Party Group of the EBMT
1Division for Pediatric Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Frankfurt, Germany,
2 Research Unit for Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of
Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria, 3NEUROFARBA Department, University of
Florence, University of Florence, Florence, Italy, 4Haematology-Oncology Department, Anna Meyer Children’s Hospital,
Florence, Italy
Primary immunodeficiency disorders that predominantly affect immune regulation and
mechanisms of self-tolerance have come into the limelight, because at least for
a subgroup of monogenetic disorders, a targeted therapy has become available.
Nevertheless, their management often involves the treatment of severely compromising,
refractory, multi-organ autoimmunity, leading to further increased susceptibility to
infections and complications of long-term immune suppressive treatment, including the
risk of malignancy. While evidence for allogeneic hematopoietic stem cell transplantation
(alloHSCT) as a curative treatment option for severely affected patients by this disease
category accumulates, clear indications, and guidelines for alloHSCT are lacking.
Predictive and stratification-relevant tools such as disease activity scores are largely
missing and often there is not a consistent genotype-phenotype correlation within
the same family to facilitate the decision whether to transplant or not. In this review,
we provide a literature-based update on indications and outcomes of alloHSCT for
congenital immune dysregulative inborn errors of immunity according to the IUIS
classification 2017.
Keywords: primary immunodeficiency, immune dysregulation, alloHSCT, IPEX, LRBA, CTLA-4, IL10R, IUIS
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INTRODUCTION
The 2017 International Union of Immunological Societies Report (IUIS) (1) on Inborn
Errors of Immunity classified diseases of immune dysregulation in to seven groups: familial
hemophagocytic histiocytotis (FLH syndromes), FLH syndromes with hypopigmentation,
regulatory T cell (Treg) defects, autoimmunity with or without lymphoproliferation, autoimmune
lymphoproliferative syndromes (ALPS), immune dysregulation with colitis, and susceptibility to
EBV and lymphoproliferative conditions. Herein, we provide an update on evidence, indication
and modalities of alloHSCT for Treg defects (IPEX, CD25-, CTLA-4-, LRBA-, BACH2-deficiency,
and STAT3 GOF); autoimmunity disorders (APECED, ITCH-, ZAP70-, TPP2-, JAK1 GOF, and
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Prolidase deficiency) and immune dysregulation with colitis
(IL-10-, IL10Ra-, IL10Rb, and NFAT 5 deficiency) based
on data from available literature via PubMed search. FLH
syndromes, ALPS and primary immune deficiency syndromes
(PID) with EBV susceptibility were excluded as they are
discussed elsewhere in this special edition (see chapter:
“Hematopoietic Stem Cell Transplantation for Primary
Hemophagocytic Lymphohistiocytosis”).
MATERIALS AND METHODS
The IUIS Phenotypic Classification for Primary
Immunodeficiencies (2017) (2) was used as the basis for
this review. Data were collected via English-language Pubmed
literature search using the name of each disorder in combination
with the terms “alloHSCT” and “transplantation.” We searched
for case reports and case series on each disorder, focusing
on evidence for alloHSCT as a treatment for the disease. For
STAT3 GOF and LRBA deficiency unpublished data were added
referring to personal communications with leading authors of
each ongoing study.
RESULTS
Treg Defects (IPEX, CD25-, CTLA-4-,
LRBA-, BACH2-Deficiency, and STAT3
GOF)
This group of diseases is dominated by conditions defined by
quantitative or qualitative impairment of the Treg compartment,
predisposing to severe multi-organ autoimmunity with or
without susceptibility to infections (Table 1). An increased risk
of malignant transformation has been reported for some of these
diseases (3, 4) and should be taken into consideration when a
patient is under assessment for transplant indication. Some of
the affected patients might present with milder symptoms and
remain stable under supportive care, nevertheless a substantial
porportion of patients develop severe complications of the
disease and immunosuppressive treatment over time which
brings them in an unfavorable starting position to undergo
alloHSCT. Therefore, early/preemptive alloHSCT should be
considered at pediatric transplant centers with expertise in
PID transplantation.
IPEX
Immune dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome is caused by mutations in FOXP3
(Forkhead-Box-Protein P3), a transcription factor that is
expressed in a subset of thymic CD4+ T-lymphocytes which
Abbreviations: AUC, Area Under the Curve; alloHSCT, Allogeneic
Haematopoeitic Stem Cell Transplantaiton; BACH2, BTB Domain And
CNC Homolog 2; CTLA 4, Cytotoxic T lymphocyte Antigen 4; IPEX,
Immunodeficiency, Polyendocrinopathy, X-linked; JAK, Janus Kinase; LRBA,
LPS-responsive Beige Like Anchor Deficiency; MAC, Myeloablative Conditioning;
NFAT5, Nuclear Factor of Activated T cells 5; RIC, Reduced Intensity
Conditioning; STAT, Signal Transducers and Activators of Transcription; VEO-
IBD, Very Early Onset Inflammatory Bowel Disease; ZAP70, Zeta Associated of
70 kDa.
are required to maintain tolerance, and prevent autoimmune
diseases (5, 6). The clinical manifestations and the response to
different therapy strategies are heterogenous, therefore treatment
of IPEX patients remains challenging without standardized
therapeutic approaches. Gambineri et al. performed an analysis
of molecular, immunologic, and clinical features in a cohort of
173 patients presenting with IPEX-like symptoms, and based
on FOXP3 gene sequencing, grouped them into IPEX kindreds
(identifiable FOXP3 mutation) and IPEX-like kindreds (without
FOXP3 mutation). In this study 44 FOXP3 variants including
nine new variants were identified in 88 IPEX patients. Among the
85 IPEX-like patients 19 disease-associated variants were found.
Even though it was not possible to differentiate major clinical
features among the two groups of patients, authors proposed a
simple flow chart to evaluate these patients and to find the most
likely molecular diagnosis (7).
Immunosuppressive therapy, the first line therapy of IPEX
patients, has been modified in the last years and new drugs have
been introduced, however, alloHSCT remains the only curative
therapy option. Barzaghi et al. published an international
multicenter retrospective study with a long-term follow-up
of IPEX patients after different therapeutic strategies. This
study included 96 genetically proven IPEX patients from whom
58 patients underwent alloHSCT (8). Patients undergoing
alloHSCT received both myeloablative (MAC) and reduced
intensity conditioning (RIC) regimens. The majority of the
patients received RIC (n = 37) including fludarabine plus
non-myeloablative doses of busulfan, treosulfan, or melphalan
or minimal intensity including fludarabine plus low dose
radiation or cyclophosphamide. MAC included busulfan (AUC
80–90mg or >14 mg/kg), cyclophosphamide, plus fludarabine,
or treosulfan. Serotherapy including Alemtuzumab or ATG was
used in 49 of the 58 patients. Fifteen patients died (26%), and the
estimated overall survival at 15 years was 73.2%. The majority of
deaths occurred early (by day +365), mainly due to infectious
complications. The type of conditioning, choice of donor, and
age at transplantation did not affect survival, whereas the clinical
status of the patients at the time of transplant, which was graded
using an organ involvement index, did have an impact on overall
survival. Acute graft vs. host disease (GVHD) was reported in
19 patients (grade III or IV in 9) while chronic GVHD was
observed in six of 52 patient who survived beyond 100 days.
Mixed chimerism was observed in 18 patients, and in 50% (9
patients) of them it was associated with complete disease control.
The T regulatory cells were 100% of donor origin in three of
these nine patients. Five of the 18 patients with mixed chimerism
have died, and four were reported to be alive with autoimmune
manifestations. Overall, a similar remission rate was observed
among patients with full (54%) or mixed (50%) chimerism. Graft
failure was observed in four patients (8). Prior to transplant
or in untransplanted patients, immunosuppressive therapy
included combinations of systemic steroids with cyclosporine
A, tacrolimus, rapamycin, azathioprine, methotrexate,
mycophenolate-mofetile, mesalazine, sulfasalazine, 6-
mercaptopurine, anti-TNF-α, anti-CD20, and abatacept.
Ten patients had completely controlled autoimmunity after
immunosuppressive therapy whereas 24 patients still had
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TABLE 1 | Treg deficiencies.
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ongoing autoimmune symptoms like enteropathy, or even
developed new autoimmune manifestations. Although the
overall survival was 86% at 15 years, the disease-free survival was
37 for untransplanted patients vs. 56% in transplanted patients.
Moreover, the persistence or the onset of new autoimmune
manifestations was high in patients under immunosuppressive
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treatment suggesting that immunosuppressive therapy can
extend life expectancy, but it is not sufficient to prevent disease
progression or associated complications.
CD 25 Deficiency
CD25 deficiency or interleukin two receptor alpha deficiency is
caused by mutations in the interleukin 2 receptor alpha (CD25)
(IL2RA) gene. The mutations result in expression of a defective α
chain or a lack of CD25 causing variable extent of autoimmunity
(9). Disease symptoms are overlapping with those of IPEX. To
our knowledge there are no published data on alloHSCT in
CD25 Deficiency.
LRBA Deficiency
Mutations in LRBA have been reported as causative for
a rather complicated multi-organ autoimmunity syndrome
with a highly variable clinical phenotype (1, 3, 10–12).
LRBA protein is involved in protein endocytosis and vesicle
transportation (10), the latter being a requirement for the
surface expression of CTLA-4 (13), another immunoregulatory
protein. Consequently, the symptoms of LRBA and CTLA-
4 deficiency syndromes are largely overlapping. Affected
individuals typically present with severe enteropathy in early
life as (very) early onset inflammatory bowel disease (V)EOIBD,
and may suffer from cytopenias, hypogammaglobulinemia,
pulmonary disease, lymphoproliferative disorder, and infancy-
onset type 1 diabetes mellitus. The risk of malignancies such as
lymphoma is increased (3, 14). The same mutations in related
or unrelated patient kindreds can present with entirely different
symptoms and severity, thus, the clinical course of each patient
remains rather unpredictable (1). Abatacept (see below) and
sirolimus were shown to be effective for most symptoms in
many individuals reported, who, however, remained dependent
on this treatment (1, 10). Nonetheless, severely affected
individuals have a significantly reduced quality of life and
show early mortality by the disease or the complications
of long-term immunosuppression. Therefore, alloHSCT as a
potentially curative treatment option for these patients should be
considered early.
Several case studies on successful alloHSCT in LRBA
deficiency are available, reporting the use of reduced toxicity
conditioning and serotherapy with a continuously rising number
of at least 25 single or small patient series reports (15–18).
An ongoing international multicenter study, comparing
the disease burden and long-term outcomes of conventional
treatment with that of alloHSCT, includes data from 24
transplanted and >50 untransplanted patients (V. Tesch and
M.G. Seidel for the ESID Registry and the EBMT Inborn
Errors Working Parties, unpublished data), still showing a
high transplant-related mortality of ∼30%. Reasons of deaths
were not specific for LRBA deficiency but included infections,
thrombotic microangioapthy, toxicity and other reasons similar
to a previous retrospective study (17). This might be in part
be due to the fact that “historical” patients in poor pre-HSCT
condition, without availability of targeted treatment and a
genetic diagnosis at time of alloHSCT, were still included in
this cohort. Both busulfan/melphalan and treosulfan with or
without thiotepa have been used, and fludarabine was included
as immunosuppressive backbone in almost all conditioning
regimens reported. A healthy heterozygous donor can be used
as a donor, although some heterozygous individuals were found
to have autoantibodies against a variety of tissues, and residual
autoimmunity in some patients persisted even after successful
allogeneic HSCT (18). To date, however, published datasets
and cohorts are too heterogenous and not large enough to
allow any recommendation regarding the exact composition of
chemotherapy drugs and the necessary level of donor chimerism
for curing LRBA deficiency.
CTLA-4 Deficiency (Haploinsufficiency)
Pathogenic mutations in CTLA-4 result in CTLA-4
haploinsufficiency causing an autosomal-dominant complex
immune dysregulation syndromewith an incomplete penetrance.
Clinical symptoms are largely overlapping with those of IPEX
and LRBA deficiency with a variable symptom complex
including early onset enteropathy, lymphoproliferation,
organ infiltration, autoimmune cytopenias, and B-lymphocyte
abnormalities, hypogammaglobulinemia, granulomatous
lymphocytic interstitial lung disease, autoimmune thyroiditis,
and arthritis (19, 20). Recently cancer prevalence of 12.9% was
documented among 184 CTLA-4 deficient patients, highlighting
the increased risk for malignant transformation, especially EBV+
lymphomas and gastric cancers (4). Abatacept, a CTLA-4–
immunoglobulin fusion protein, ameliorates disease symptoms
in CTLA-4 (and LRBA deficiency) to variable extent, as abatacept
is a soluble version of CTLA-4 itself and is considered as a
CTLA-4 replacement therapy (21). A few patients were reported
receiving abatacept for gastrointestinal disease with partial
improvement with a dosing of 30 mg/kg 2-weekly (bi-weekly).
Belatacept might be an alternative. A recent publication on 22
LRBA-deficient patients receiving abatacept (children and young
adults) showed that 16 patients achieved long-term complete
control of lymphoproliferation and chronic diarrhea, especially
autoimmune cytopenias. Weekly or bi-weekly administration
of abatacept were associated to a better disease control than
4-weekly injections. There were no serious side effects related
to the abatacept therapy. Circulating T follicular helper cell
frequencies were found to be a reliable biomarker of disease
activity, which decreased on abatacept therapy in most subjects
(22). Studies on belatacept treatment, especially for pediatric
patients are not available yet. Further prospective studies are
crucial in order to assess the clinical value of abatacept/belatacept
treatment as monotherapy and/or a bridge to transplant for
severely affected CTLA-4 patients.
Large studies on transplanted CTLA-4 patients are not
available yet. In a cohort of eight patients, seven individuals
could be rescued by alloHSCT, with six patients having a
complete remission of their symtoms and one patient showing
partial response. RIC included combinations of treosulfan plus
fludarabine with or without thiotepa, but also fludarabine plus
melphalan and serotherapy. In this cohort, four of eight patients
experienced GVHD despite having well-matched donors and
receiving appropriate GVHD prophylaxis in three out of four
cases. Based on their personal experience, the authors in this
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study suggested that a high level of inflammation in these patients
might have contributed to the development of alloreactivity and
so future patients are likely to benefit from either enhanced
pre-HSCT immunosuppression or more aggressive post-HSCT
GVHD prophylaxis (23).
Schwab et al. reported five transplanted patients among
90 affected CTLA4 mutation carriers undergoing alloHSCT
between 10 and 50 years of age, due to uncontrollable
cytopenia, enteropathy, and lymphoma with additional
autoimmune disorders involving lymphoproliferative and
infectious complications (20).
STAT3 GOF
Somatic activating gain-of-function (GOF) STAT3 mutations
in the SH2 domain have been described in patients with
T-lymphocyte and NK- cell Large Granular Cell Leukemia
characterized by adult-onset lymphoproliferation, as well as
autoimmunity with immune-mediated cytopenias (24). Genome
wide association studies (GWAS) have also linked a STAT3
polymorphism to inflammatory bowel diseases (IBD) (25).
In this manuscript, we focus on heterozygous germline
activating mutations in STAT 3 (STAT3 GOF) as a cause of a
syndrome of early onset autoimmunity and lymphoproliferation
with highly variable penetrance. Symptoms include early
onset enteropathy, lymphocytic interstitial lung disease, and
autoimmune cytopenias, associated with growth delay in some
patients, endocrinopathies (diabetes), hepatic dysfunction, and
susceptibility to opportunistic infections includingmycobacterial
disease and retention of deciduous teeth. On laboratory work up,
hypogammaglobulinemia, associated with decreased switched
memory B lymphocytes, NK cells and plasmacytoid dendritic
cells have been reported as well as T-lymphocytopenia, dendritic
cell deficiency, variable Th17 lymphocyte numbers, and low
circulating eosinophils were observed as well (26–28). Despite
the connection between increased STAT3 activity and neoplastic
disease, as well as the observation that somatic GOF mutations
in STAT3 lead to malignancies, neoplastic disease was quite
rare in previously reported cohorts. One patient developed T-
lymphocyte large granular lymphocytic leukemia at age 14. With
regard to treatment options, a blockade of IL-6 activation with
tocilizumab seems to ameliorate disease symptoms intermittently
by reduction of TH-17 numbers to normal levels. Recent
data show that JAK-inhibitors (e.g., ruxolitinib) could be an
interesting alternative with positive impact on disease symptoms
(29, 30).
There are published data on alloHSCT in two patients; one
was curative with complete resolution of autoimmune symptoms
and the other patient died of adenovirus infection and refractory
graft vs. host disease (28).We are aware of unpublished data from
18 STAT3 GOF patients from 11 centers (international survey)
who received alloHSCT with 61% survival. Causes of death were
mainly infection complications and GVHD. Most of the patients
received combinations of fludarabine plus treosulfan or busulfan
and serotherapy in a myeloablative reduced toxicity manner.
There was no superior conditioning (Personal communication
with J. Heimall and L. Forbes Satter).Of note, growth retardation
by STAT3 GOF in some of the affected patients might remain
uncorrected by alloHSCT.
BACH 2 Deficiency (Haploinsufficiency)
BACH 2 is a transcription factor participating in oxidative stress-
mediated apoptosis and is involved in macrophage-mediated
innate immunity as well as the adaptive immune response. It is
essential for T- and B-lymphocytes. Single nucleotide variants in
the BACH2 locus associate with multiple autoimmune diseases.
BACH 2 haploinsufficiency was recently reported causing
primary immunodeficiency syndrome of immunodeficiency and
autoimmunity, especially with intestinal inflammation (31). To
our knowledge larger cohorts of BACH2 deficient patients and/or
experience with alloHSCT are not published yet.
Autoimmunity Disorders (APECED, ITCH-,
ZAP70-, TPP2-, JAK1 GOF, and Prolidase
Deficiency)
This section describes PID with autoimmunity including
monogenetic diseases of the immune system affecting self-
tolerance by thymic impairment (e.g., APECED) and/or other
T-lymphocyte function deficiencies (ZAP70), syndromic diseases
(JAK1 GOF) or metabolic diseases (Prolidase deficiency)
(Table 2).
There is no indication for alloHSCT for APECED
(AIRE deficiency), since there is an intrinsic impairment of
thymic function. Management includes antifungal therapy
and symptomatic treatment of associated endocrine and
autoimmune abnormalities.
ITCH Deficiency
ITCHY E3 Ubiquitin protein ligase (ITCH) encodes for ITCH
protein transferring ubiquitin from E2 ubiquitin-conjugating
enzymes to protein substrates. ITCH targets specific proteins
for lysosomal degradation and plays a role in multiple cellular
processes including erythroid and lymphoid cell differentiation
and the regulation of immune responses. Mutations in this gene
are a cause of syndromic multisystem autoimmune disease. To
our knowledge, the largest reported cohort includes 10 patients
with an homozygous mutation in ITCH having autoimmunity
and morphologic and developmental abnormalities (32).
Characteristical clinical features included dysmorphic facies,
macrocephaly, failure to thrive, hepatomegaly, splenomegaly,
and delayed motor development. Six of ten patients required
enteral nutrition via gastrostomy tube placement within the first
year of life due to failure to thrive, although only two had severe
symptoms of malabsorption. There are no reported cases of
alloHSCT for ITCH deficiency yet.
TPP2 Deficiency
Tripeptidyl Peptidase 2 (TPP2) is coding the TPP2 protein which
is a serine exopeptidase involved in extralysosomal peptide
degradation. Its deficiency in mice activates cell death programs
and premature senescence. Likewise, the human TPP2 deficiency
is a PID linking premature immunosenescence to severe
autoimmunity. The first description of this disease included two
affected siblings. One developed severe viral infections (HSV,
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TABLE 2 | Autoimmunity with or without Lymphoproliferation.
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Prolidase
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JAK inhibitors Not reported Not reported
VZV) in addition to autoimmunity, leading to the indication
for alloHSCT at 10 years of age. AlloHSCT was performed
using fludarabine, targeted low levels of busulfan, thiotepa, and
antithymocyte globulin. Disease symptoms could be cured by
alloHSCT (33).
Larger series of transplanted TPP2 patients are not available
yet. Of note, some TPP2 patients showed neurodevelopmental
delay. A recent study of a large cohort of patients with multiple
sclerosis (MS) could identify TPP2 mutations as causative
in three affected siblings of a consanguineous Syrian family.
Authors concluded that a sterile brain inflammation due to
TPP2 deficiency mimicks MS (34). Whether these patients would
benefit from alloHSCT has not been assessed yet.
Prolidase Deficiency
Prolidase deficiency is a rare metabolic condition characterized
by mutations in the PEPD gene resulting in disturbed
collagene formation. Clinical symptoms include skin lesions,
recurrent infections, unusual facial features, and variable
intellectual disability. Patients seem to develop a variable
degree of immunedysregulation, presenting as systemic Lupus
erythematodes (SLE) as it was described in 10 patients having
a SLE-like disease (35). Furthermore, a case of VEOIBD in
presence of TTP2 deficiency was described in a toddler (36).
We are not aware of any data on possible correction of disease
symptoms by alloHSCT.
ZAP70
ZAP70 (zeta associated of 70 kDa) is a tyrosine kinase expressed
by thymocytes, T- and NK- cells. ZAP70 deficiency results
in a clinical picture of (severe) combined immunodeficiency
(S)CID with abnormal T-cell receptor signaling and abnormal
maturation and function of thymocytes. Characteristically, there
are low to absent CD8+ lymphocytes with normal numbers of
CD3+ and CD4+ T-lymphocytes; with disturbed response to
mitogens and antigens.
Cuvelier et al. reported in a single center retrospective
study of eight patients with confirmed ZAP70 deficiency
receiving alloHSCT with and without conditioning. At a
median follow-up of 13.5 years, all patients were alive. Patients
receiving myeloablative conditioning regimens with busulfan
and cyclophosphamide or fludarabine achieved and maintained
100 % chimerism for T-, B-lymphocytes and myeloid cells.
Patients who received unconditioned transplants showed stable
mixed donor chimerism for T-lymphocytes but engraftment
of myeloid cells did not occur or was at least low in all of
the patients. One patient had received ATG as serotherapy.
Six of eight patients developed acute GVHD II/III, and two
Frontiers in Pediatrics | www.frontiersin.org 6 November 2019 | Volume 7 | Article 461
Bakhtiar et al. alloHSCT for Immune Dysregulatory PID
patients were reported having limited chronic GVHD, whereas
two patients developed extensive cGVHD (resolved eventually).
Seven of eight patients achieved stable IgG levels without need
for immunoglobulin replacement (37).
Brager et al. collected data on 19 patients with ZAP70
deficiency of whom 16 patients underwent alloHSCT in
seven different countries. Prior to alloHSCT all patients
presented with repeated fungal and microbial infections and
one patient with lymphoma. Patients who received myeloablative
conditioning showed complete immune reconstitution, while
lack of conditioning failed or resulted in partial immune
reconstitution. In conclusion, these data showed favorable long-
term outcomes in patients with ZAP70 deficiency receiving
alloHSCT after conditioning (38).
JAK 1 GOF
The JAK/STAT interplay plays an important role in cytokine an
growth factor signaling and controls hematopoiesis and immune
function with activating somatic mutations being relevant for
hematological myeloid malignancies (39). Germline JAK1 gain-
of-function mutations cause a PID syndrome with autosomal
dominant immune dysregulation and hypereosinophilia with
eosinophilic infiltration of the gastrointestinal tract, massive
hepatosplenomegaly and severe atopic dermatitis that can be
successfully treated with ruxolitinib, an oral JAK1/2 inhibitor
(40). To our knowledge there is no report on alloHSCT for JAK1
GOF to date.
Immune Dysregulation With Colitis (IL-10-,
IL10Ra-, IL10Rb, and NFAT 5-Deficiency)
In this section we discuss diseases with a distinc phenotype of
inflammatory bowel disease including the “IL-10 group” of IL-
10 and IL-10 receptor alpha and beta deficiency as well as the
haploinsufficincy of NFAT5 (Table 3).
IL10 and IL-10R a/b Deficiency
IL-10 being secreted by monocytes, macrophages, T-, B-
lymphocytes, dendritic, epithelial and mast cells, is a crucial anti-
inflammatory cytokine largely contributing to the maintenance
of immune homeostasis via metabolic reprogramming of
macrophages (41). Mutations in IL-10 and IL-10 R have
been described as causative for severe VEOIBD (42, 43).
Human inherited IL-10 receptor deficiency was also associated
with a high risk of non-EBV–related diffuse large B-cell
lymphoma suggesting that IL-10 signaling may be involved
in the immune control of germinal center B-cell lymphoma
(44). Engelhardt et al. presented a series of patients with IL-
10 or IL-10R mutations suffering from symptoms of VEOIBD
resulting in a complicated treatment-refractory IBD with
fistulae, abscesses and significant fissures resulting in marked
weight loss and growth retardation. This work included three
transplanted patients, all being successfully treated resulting in
complete remission of disease symptoms after myleoablative
conditioning using blusulfan plus fludarabin and ATG in one
patient, and fludradabine plus melphalan, and alemtuzumab
in two others. All three patients showed stable engraftment
with full donor chimerism without severe organ toxicity or
higher grade GVHD. Authors concluded that because of the
colitis being refractory to the standard immunosuppressive
therapy, alloHSCT should be considered early as a curative
therapeutic option (45). Kocacık Uygun et al. described
two patients with IL-10 R deficiency, suffering from severe
malnutrition and colon fistulae, who lacked a MSD and
received alloHSCT from a MUD after MAC with busulfan
(16 mg/kg), fludarabine (180 mg/m2) and ATG-Fresenius
(30 mg/kg), and GVHD prophylaxis using cyclosporine and
methotrexate (10 mg/m2 days 1, 3, and 6). Both patients showed
an uncomplicated course of transplantation with remission of
disease symptoms after early and stable engraftment with full
donor chimerism (46).
Kotlarz et al. described five patients (out of a cohort of
16 IL10/IL-10R deficient patients) undergoing alloHSCT using
a “standard” transplant protocol including alemtuzumab (1
mg/kg), fludarabine (180 mg/m2), treosulfan (42 g/m2), and
thiotepa (10 mg/kg) and strict gut decolonization with colistin,
amphotericin B (oral), ciprofloxacin, metronidazole, vancomycin
(oral), and fluconazole. Furthermore, total parenteral nutrition
was administered during the peritransplantation period. GVHD
prophylaxis included cyclosporine and mycophenolate mofetil.
All five patients survived without severe complications of
TABLE 3 | Autoimmune dysregulation with colitis.
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No B cell lymphomas 10–100
NFAT5 haploinsufficiency
(NFAT5)
604708 AD Autoimmune enteropathy




No Not reported Not reported
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alloHSCT. One patient needed a second transplantation (same
donor) because of graft rejection at day+86 (47).
Karaca et al. reported a successful course of transplant in
a female patient receiving reduced toxicity conditioning with
busulfan (4 mg/kg/day) and fludarabine (40 mg/m2/day), and
rabbit ATG (Fresenius) 10 mg/kg/day (48).
In conclusion, the course of the disease of these 11
transplanted patients is suggesting that early alloHSCT seems
to be the only curative option for patients with IL-10/IL-10
receptor deficiencies. Reduced intensity or toxicity conditioning
plus serotherapy should be used.
NFAT5
NFAT5 is a transcription factor with a pivotal role in regulating
immune system in response to physiological and pathologic
osmotic stress, even in relation to dieteray sodium excess. An
essential role has been assigned to NFAT5 in immunity and
autoimmune diseases, especially due to its known relevance
for macrophage activation and survival, Treg generation, and
TH17 differentiation. As a primary immunodeficiency syndrome,
NFAT5 haploinsufficiency was recently described primarily
presenting with IBD and autoimmunity (49), however, further
published data on affected patients and on alloHSCT are not
available to date.
DISCUSSION
The list of monogeneic immune dysregulative PID is rapidly
expanding with the increasing availability of next generation
sequencing. As our ability to establish a genetic diagnosis
is improved, the challenge of linking genotype to phenotype
and, consequentially, to a specific standard treatment, arises, a
challenge that is made difficult by the small numbers of patients
and complicated underlying pathophysiology of these diseases.
Therefore, standardized treatment protocols, prognostication
and unique treatment decisions are not available. Serious multi-
organ autoimmunity and infectious complications of long-term
immunosuppressive treatment can be life threatening. Today,
targeted treatment such as abatacept or JAK inhibition might
ameliorate symptoms in a porportion of patients, however,
alloHSCT remains the only curative treatment option for most
of the severely affected patients. It is to be expected that
patients having multi-organ autoimmunity in their first decade
of life, progress to a more severe disease complex with early
manifestation of irreversible organ damage due to autoimmunity
and complications of long-term immunosuppressive treatment.
Therefore, the indication to proceed to alloHSCT remains a
clinical decision, which (regardless of the final decision) should
be evaluated in specialized pediatric PID-HSCT centers.
For IPEX, CTLA-4, and LRBA deficiency there is encouraging
evidence for alloHSCT, especially if carried out early and when
little “organ morbidity” with a low disease activity (8) is present.
Various attempts to score the extent of immunodeficiency and
dysregulation activity with one of the aims being to facilitate
decisions to transplant have been and are being undertaken, e.g.,
within the retrospective IPEX study (8), the prospective study
on profound combined immunodeficiencies (PCID) (50), and
ongoing studies on CTLA-4 and LRBA deficiency (unpublished
data).Whereas a common themewas that patients with advanced
stages of poorly controlled PID with immune dysregulation
(infections or autoimmunity) had worse outcomes in alloHSCT,
one may argue that untransplanted patients will have a
life-long, accumulating disease- and treatment-related toxicity
burden, and a similarly unpredictable individual course as in
alloHSCT. Thus, in conclusion, a patient with IPEX, LRBA
deficiency, and probably also CTLA4 deficiency should undergo
alloHSCT evaluation and donor search upon diagnosis, and,
ideally, an attempt to ameliorate disease severity by targeted
immunosuppressive treatment should be undertaken before
alloHSCT. But the weaker a genotype-phenotype correlation and
the better an available targeted treatment is, the more difficult
will it be to counsel patient families on the specific transplant
indication and urgency.
ZAP70 deficient patients might remain undetected in TREC-
based Newborn Screening and present at later age with infectious
complications and/or malignancies. However, alloHSCT should
be considered early. RIC should be used to provide stable
trilineage engraftment and immune reconstitution.
For STAT1/STAT3 GOF there is cumulative evidence for
JAK inhibition, which should be initiated to evaluate the
clinical response but also to reduce disease activity prior to
alloHSCT. For patients suffering from IL-10/IL-10 receptor
deficiencies, early alloHSCT should be carried out using reduced
toxicity myeloablative or submyeloablative conditioning and
serotherapy as there has been growing evidence throughout
recent years showing unresponsiveness of colitis to the
standard treatment.
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